CyTOF®: A new tool to decipher the immunomodulatory activity of daratumumab
Castella, B., Mina, R., and Gay, F.
CD38‐targeted therapy is emerging as one of the most effective immunotherapies ever developed for the treatment of multiple myeloma (MM). CD38 is a transmembrane glycoprotein that serves as a receptor with a multifunctional ecto‐enzymatic activity, which is highly expressed on plasma‐cells, but also on several other cells belonging to the hemopoietic as well as to the non‐hemopoietic tissues.
Daratumumab, a fully human IgG1‐kappa monoclonal antibody, is the first‐in‐class antibody targeting CD38. It has rapidly become a cornerstone of the anti‐MM treatment, showing activity both as single agent in heavily pretreated MM patients and in combination with other agents.
Castella, B., Mina, R., and Gay, F. "CyTOF®: A new tool to decipher the immunomodulatory activity of daratumumab" Cytometry Part A (2019): doi: 10.1002/cyto.a.23752